Huang, D-D <br/><br/>
Liraglutide improves myocardial fibrosis after myocardial infarction through inhibition of CTGF by activating cAMP in mice.  [electronic resource] 

 -  European review for medical and pharmacological sciences  07 2018 
 - 4648-4656 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2284-0729 
<br/><br/><label>Standard No.: </label>10.26355/eurrev_201807_15524  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Connective Tissue Growth Factor--antagonists & inhibitors<br/>Cyclic AMP--physiology<br/>Fibrosis<br/>Hypoglycemic Agents--pharmacology<br/>Liraglutide--pharmacology<br/>Male<br/>Mice<br/>Mice, Inbred C57BL<br/>Myocardial Infarction--drug therapy<br/>Myocardium--pathology<br/>Transforming Growth Factor beta1--genetics<br/>Ventricular Remodeling--drug effects